Supraventricular Tachycardia Without Preexcitation as a Cause of Sudden Cardiac Arrest in Pediatric Patients

Choi, Nak Hyun; Silver, Eric S.; Liberman, Leonardo

doi:10.1007/s00246-021-02720-z

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a subgroup of patients with SVTs with a rapid ventricular rate in which cardiac arrest may be a manifestation even in pediatric patients. Thus, electrophysiology testing must be considered, especially in the pediatric population ( 68 ). There is evidence of an increased incidence of ventricular arrhythmias and SCD in COVID-19 patients ( 69 ), while a recent meta-analysis found a higher prevalence of SCD during the COVID-19 pandemic compared to the pre-pandemic period ( 70 ).…”

Section: Discussionmentioning

confidence: 99%

Risk and Protective Factors for Sudden Cardiac Death: An Umbrella Review of Meta-Analyses

Tsartsalis

Korela

Karlsson

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundSudden cardiac death (SCD) is a global public health issue, accounting for 10–20% of deaths in industrialized countries. Identification of modifiable risk factors may reduce SCD incidence.MethodsThis umbrella review systematically evaluates published meta-analyses of observational and randomized controlled trials (RCT) for the association of modifiable risk and protective factors of SCD.ResultsFifty-five meta-analyses were included in the final analysis, of which 31 analyzed observational studies and 24 analyzed RCTs. Five associations of meta-analyses of observational studies presented convincing evidence, including three risk factors [diabetes mellitus (DM), smoking, and early repolarization pattern (ERP)] and two protective factors [implanted cardiac defibrillator (ICD) and physical activity]. Meta-analyses of RCTs identified five protective factors with a high level of evidence: ICDs, mineralocorticoid receptor antagonist (MRA), beta-blockers, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with HF. On the contrary, other established, significant protective agents [i.e., amiodarone and statins along with angiotensin-converting enzyme (ACE) inhibitors in heart failure (HF)], did not show credibility. Likewise, risk factors as left ventricular ejection fraction in HF, and left ventricular hypertrophy, non-sustain ventricular tachycardia, history of syncope or aborted SCD in pediatric patients with hypertrophic cardiomyopathy, presented weak or no evidence.ConclusionsLifestyle risk factors (physical activity, smoking), comorbidities like DM, and electrocardiographic features like ERP constitute modifiable risk factors of SCD. Alternatively, the use of MRA, beta-blockers, SGLT-2 inhibitors, and ICD in patients with HF are credible protective factors. Further investigation targeted in specific populations will be important for reducing the burden of SCD.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020216363, PROSPERO CRD42020216363.

show abstract

Section: Discussionmentioning

confidence: 99%